Genmab A/S: Preliminary Analysis of Data Evaluating Investig

Preliminary analysis of data from the EPCORE NHL-2 study demonstrates patients with previously untreated follicular lymphoma (FL) who received epcoritamab in combination with rituximab-lenalidomide

Related Keywords

United States , Japan , Boston , Massachusetts , Chicago , Illinois , Denmark , Copenhagen , Køavn , Canada , American , America , Judith Klimovsky , Hematol Hemoter , Asia Pacific , Joshua Brody , David Freundel , Andrew Carlsen , Drug Administration , Lymphoma Research Foundation , Leukemia Lymphoma Society , Genmab Us Inc , American Society Of Clinical Oncology , Linkedin , Global Communications Corporate Affairs , Data From The Observational National Lymphocare Study , Exchange Commission , Abbvie Biotechnology Ltd , Clinical Oncology , Annual Meeting , Mount Sinai Hess Center , Priority Review , Biologics License Application , Follicular Lymphoma , Medication Guide , North America , Media Release , Annual Report , Y Shaped Genmab , Abbvie Biotechnology , Opin Med , Leukemia Lymphoma , Accessed March , Subsequent Therapy , Data From , Observational National Lymphocare , Treatment Patterns , Patients With Diffuse Largeb Cell Lymphoma , Bras Hematol , Relapsed Follicular Lymphoma , Marginal Zone Lymphoma , Senior Director , Vice President , Investor Relations , Ihr Portfolio ,